Brian G. Till

TL;DR: The results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T- cell receptor and neomycin resistance gene show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach.

TL;DR: A pilot clinical trial testing a "third-generation" CD20-specific CAR with CD28 and 4-1BB costimulatory domains in patients with relapsed indolent B-cell and mantle cell lymphomas found that adoptive immunotherapy with CD 20-specific T cells was well tolerated and was associated with antitumor activity.

TL;DR: Patients with relapsed/refractory B-ALL enrolled in a phase 1/2 clinical trial evaluating lymphodepletion chemotherapy followed by CD19 CAR T-cell therapy who might benefit from consolidation strategies such as allogeneic HCT are studied.

TL;DR: Results demonstrate that cTCR signal strength, and consequently Ag sensitivity, can be modulated by differential choice of target epitopes with respect to distance from the cell membrane, allowing discrimination between targets with disparate Ag density.

TL;DR: This study provides the preclinical basis for a clinical trial of adoptive T cell immunotherapy for patients with relapsed CD20+ mantle cell lymphoma and indolent lymphomas and verified the superiority of generating genetically modified polyclonal T cells expressing the second-generation cTCR rather than T cell clones.